Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634877 · ClinicalTrials.gov registry record · Phase 3
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
A Phase 3 study of Endometrial Neoplasms, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 990
- Enrollment target
- 20
- Study locations
NCT04634877 is a Phase 3 study of Endometrial Neoplasms that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 990 participants, above the 305-participant average among 14 other Endometrial Neoplasms trials with a reported enrollment target (225% higher). The trial reports 20 study locations across 15 states.
The verdict
NCT04634877, a Phase 3 study of Endometrial Neoplasms, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 990 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to overall survival (OS). The primary hypotheses are that pembrolizumab + adjuvant chemotherapy is superior to placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to DFS as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recurrence, and with respect to OS.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- DRUG Carboplatin
- DRUG Docetaxel
- DRUG Paclitaxel
- DRUG Placebo for pembrolizumab
Study Locations (20)
New York
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 3076) - Mineola
- Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 3042) - New York
- Montefiore Medical Center ( Site 3065) - The Bronx
Alabama
- University of Alabama - Birmingham ( Site 3061) - Birmingham
- University of South Alabama, Mitchell Cancer Institute ( Site 3058) - Mobile
Arizona
- HonorHealth Research Institute - Biltmore ( Site 3043) - Phoenix
- Arizona Oncology Associates PC- HOPE ( Site 3049) - Tucson
Indiana
- Parkview Cancer Institute ( Site 3067) - Fort Wayne
- Indiana University Melvin and Bren Simon Cancer Center ( Site 3071) - Indianapolis
California
- UCSD Moores Cancer Center ( Site 3053) - La Jolla
Colorado
- University Of Colorado ( Site 3051) - Aurora
Connecticut
- Smilow Cancer Hospital at Yale New Haven ( Site 3070) - New Haven
Florida
- Mount Sinai Cancer Center ( Site 3081) - Miami Beach
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 990 participants |
| Start Date | 2021-01-10 |
| Est. Completion | 2026-09-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04634877
The ClinicalTrials.gov registry entry for NCT04634877 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 990 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 305-participant average among 14 other Endometrial Neoplasms trials with a reported enrollment target (225% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Endometrial Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT04634877 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT04634877 about?
NCT04634877 is a clinical study titled "Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)". The purpose of this study is to compare pembrolizumab + adjuvant chemotherapy with placebo + adjuvant chemotherapy, with or without radiotherapy, with respect to disease-free survival (DFS) as assessed radiographically by the investigator or by histopathologic confirmation of suspected disease recur...
What is the current status of trial NCT04634877?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 990 participants. The study started on 2021-01-10. Estimated completion is 2026-09-15.
What conditions does trial NCT04634877 study?
This clinical trial studies the following conditions: Endometrial Neoplasms.
What interventions are being tested in trial NCT04634877?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Carboplatin (DRUG), Docetaxel (DRUG), Paclitaxel (DRUG), Placebo for pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT04634877?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04634877 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
ACTIVE NOT RECRUITING · Phase 3
-
A Study of LY4175408 in Participants With Advanced Cancer
RECRUITING · Phase 1
-
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RECRUITING · Phase 1
-
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.